Skip to content
AnalystLens

Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2023

Filing Date
Filed February 20, 2024
Period End
December 31, 2023
Security
HALO
One revenue dollarkept$0.34
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Material agreement8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 10-K filed February 20, 2024. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. reported full-year 2023 total revenues of $829.3 milliona, up from $660.1 million in 2022, with net income of $281.6 million (diluted EPS $2.10) compared with $202.1 million in 2022.

Royalties rose to $447.9 millionb from $360.5 million, driven by continued uptake of DARZALEX SC by Janssen and Phesgo by Roche and new device royalties from the Antares acquisition. Total product sales, net, increased to $300.9 million from $191.0 million, led by proprietary products (XYOSTED and Hylenex) and bulk rHuPH20 sales. Revenues under collaborative agreements declined to $80.5 million from $108.6 million, reflecting the timing of milestones.

The company's balance sheet carries $1,499.2 millionc of net long-term debt, consisting of 2027 and 2028 Convertible Notes with total principal of $1,525.0 million, against cash, cash equivalents and marketable securities of $336.0 million. Management states these resources are sufficient to fund operations for at least the next 12 months. Stockholders' equity fell to $83.8 million from $169.8 million, largely due to $402.4 million of share repurchases in 2023.

In February 2024, the board authorized a new $750.0 milliond capital return program. Key risks highlighted include dependence on partners' regulatory approvals and commercialization, reliance on rHuPH20 as the core technology underlying most ENHANZE revenues, single-source contract manufacturers for bulk rHuPH20, and the Alexion and Horizon collaboration terminations effective in 2024. Customer concentration is significant, with one partner accounting for 44% of 2023 total revenues.

Key Highlights

  1. Total revenues rose to $829.3 million in 2023 from $660.1 million in 2022.
  2. Royalties increased 24% to $447.9 million, driven by DARZALEX SC (Janssen) and Phesgo (Roche) sales and device royalties from Antares.
  3. Total product sales, net, rose 57% to $300.9 million, including $130.8 million from proprietary products and $115.4 million from bulk rHuPH20.
  4. Net income was $281.6 million (diluted EPS $2.10), compared with $202.1 million (diluted EPS $1.44) in 2022.
  5. Long-term debt carrying value was $1,499.2 million against $336.0 million of cash, cash equivalents and marketable securities at year-end.
  6. Company repurchased $402.4 million of common stock in 2023 and authorized a new $750.0 million capital return program in February 2024.
  7. Alexion and Horizon notified discontinuation of their collaboration agreements, effective in early 2024; one partner represented 44% of total 2023 revenues.

Follow one dollar

Of each $1.00 of revenue in FY2023, Halozyme Therapeutics kept $0.34.

  1. Revenue$829.3M100.0%
  2. Cost of revenue−$192.4M23.2%
  3. Gross profit$636.9M76.8%
  4. Operating costs−$299.3M36.1%
  5. Operating income$337.6M40.7%
  6. Interest, other & tax−$56.0M6.8%
  7. Net income$281.6M34.0%
Computed from 10-KFY2023filed February 20, 2024Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2023 revenue went

$829.3M
  • Net income: $281.6M, 34% of revenue
  • Cost of revenue: $192.4M, 23% of revenue
  • SG&A: $149.2M, 18% of revenue
  • R&D: $76.4M, 9.2% of revenue
  • Other operating costs: $73.8M, 8.9% of revenue
  • Interest, other & tax: $56.0M, 6.8% of revenue

Kept 34% as net income

Full revenue history →

Financial Statements

FY2023 against FY2022

Line itemFY2023FY2022Change
Revenue$829.25M$660.12M+25.6%
Cost of Revenue$192.36M$139.30M+38.1%
Gross Profit$636.89M$520.81M+22.3%
R&D Expenses$76.36M$66.61M+14.6%
SG&A Expenses$149.18M$143.53M+3.9%
Operating Expenses$491.68M$392.58M+25.2%
Operating Income$337.57M$267.53M+26.2%
Interest Expense$18.76M$16.95M+10.7%
Net Income$281.59M$202.13M+39.3%
EPS (Basic)$2.13$1.48+43.9%
EPS (Diluted)$2.10$1.44+45.8%
Shares Outstanding (Basic)131.93M136.84M−3.6%
Shares Outstanding (Diluted)134.20M140.61M−4.6%

Frequently Asked Questions

  1. What drove the growth in Halozyme's revenue in 2023?

    Royalties increased $87.4 million to $447.9 million, primarily from DARZALEX SC and Phesgo sales and new device royalties from the Antares acquisition. Product sales, net increased $109.8 million to $300.9 million, driven by proprietary products, device partnered products and higher bulk rHuPH20 sales. Collaborative agreement revenue declined $28.1 million to $80.5 million due to milestone timing.

  2. How much debt does Halozyme carry and when is it due?

    Convertible notes total $1,525.0 million in principal: $805.0 million of 0.25% notes due 2027 and $720.0 million of 1.00% notes due 2028. The carrying value of long-term debt is $1,499.2 million. The 2022 Credit Agreement's revolving facility, which had a $575 million capacity, was undrawn at December 31, 2023.

  3. Does the company have enough cash to fund operations?

    Management states that cash, cash equivalents and marketable securities of $336.0 million will be sufficient to fund operations for at least the next 12 months, and expects to fund operations from existing cash, partner revenues and potential future financings.

  4. What are the main risks to Halozyme's business?

    Key risks include delays or failures in partners' regulatory approvals, adverse developments involving the rHuPH20 enzyme that underlies most ENHANZE revenue, supply disruptions from single-source contract manufacturers, termination of key collaboration agreements, and dependence on partners to commercialize products. The filing also notes the risk of dilution from convertible note conversion and stock price volatility.

  5. What capital return actions did the company take?

    In 2023 the company repurchased 4.2 million shares for $150.0 million in open-market transactions and accelerated the remaining $250.0 million under an accelerated share repurchase agreement, with initial delivery of 5.5 million shares. In February 2024, the board authorized a new program to repurchase up to $750.0 million of common stock. The company has never paid dividends.